BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10669673)

  • 21. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
    Wang YT; Huang G
    Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
    Nguyen VH; Peloquin S; Lacasse Y
    Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Makler PT
    J Nucl Med; 1997 Jul; 38(7):1173-4. PubMed ID: 9225819
    [No Abstract]   [Full Text] [Related]  

  • 24. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
    Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany.
    Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
    Eur J Nucl Med; 2000 Oct; 27(10):1441-56. PubMed ID: 11083532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
    Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
    Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
    Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
    J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost-effectiveness of PET in the management algorithms of lung tumors: comparison of health economic data].
    Dietlein M; Moka D; Weber K; Theissen P; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):122-8. PubMed ID: 11556202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.
    Kahn D; Menda Y; Kernstine K; Bushnell D; McLaughlin K; Miller S; Berbaum K
    Chest; 2004 Feb; 125(2):494-501. PubMed ID: 14769730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The optimal timing of FDG-PET/CT in non-small cell lung cancer diagnosis and staging in an Australian centre.
    Johnson A; Norman R; Piccolo F; Manners D
    BMC Pulm Med; 2021 Jul; 21(1):209. PubMed ID: 34210303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck.
    Hollenbeak CS; Lowe VJ; Stack BC
    Cancer; 2001 Nov; 92(9):2341-8. PubMed ID: 11745289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of positron emission tomography for lung cancer staging.
    Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
    Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
    Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
    Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan].
    Kubota K; Yamada S; Fukuda H; Tanida T; Saitou Y; Takahashi J; Yamada K
    Kaku Igaku; 1997 May; 34(5):329-36. PubMed ID: 9248260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.